<!doctype html>
<html lang="en">
<head>
  <meta http-equiv="x-ua-compatible" content="ie=edge">
  <title>Trineurotec | Oroxylin A improves attention deficit hyperactivity disorder-like behaviors in the spontaneously hypertensive rat and inhibits reuptake of dopamine in vitro</title>
  <meta name="description" content="">
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <meta property="og:title" content="Oroxylin A improves attention deficit hyperactivity disorder-like behaviors in the spontaneously hypertensive rat and inhibits reuptake of dopamine in vitro">
  <meta property="og:type" content="website">
  <meta property="og:url" content="/posts/oroxylin-a-improves-attention">
  <meta property="og:description" content="">
  <meta property="og:site_name" content="Trineurotec">
  <meta property="og:image" content="">

  <meta name="twitter:card" content="summary">
  <meta name="twitter:url" content="/posts/oroxylin-a-improves-attention">
  <meta name="twitter:title" content="Oroxylin A improves attention deficit hyperactivity disorder-like behaviors in the spontaneously hypertensive rat and inhibits reuptake of dopamine in vitro">
  <meta name="twitter:description" content="">
  <meta name="twitter:image" content="">

  <link rel="icon" type="image/png" href="/assets/logo.png"/>
  <link href="/feed.xml" type="application/rss+xml" rel="alternate" title="Trineurotec Last 10 blog posts" />
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">

  
    <link rel="stylesheet" href="/assets/fonts.css">

  

  
    <link rel="stylesheet" href="/assets/light.css">

  
</head>

<body>
  <main>
    <div class="grid grid-centered">
      <div class="grid-cell">
        <nav class="header-nav ">
  <a href="/" class="header-logo" title="Trineurotec" style="">Trineurotec</a>
  <ul class="header-links">
    <li><a href="/about_en" title="About me">About</a></li>
    <li><a href="/products_en" title="About me">Products</a></li>
    <li><a href="/research_en" title="About me">Research</a></li>
    <li><a href="/contact_en" title="About me">Contact</a></li>
  </ul>
</nav>

        <article class="article ">
          <header class="article-header">
            <h1>Oroxylin A improves attention deficit hyperactivity disorder-like behaviors in the spontaneously hypertensive rat and inhibits reuptake of dopamine in vitro</h1>
            <p>Yoon SY, dela Peña I, Kim SM, Woo TS, Shin CY, Son KH, Park H, Lee YS, Ryu JH, Jin M, Kim KM, Cheong JH</p>
            <div class="article-list-footer">
              <span class="article-list-date">
                January 10, 2013
              </span>
              <span class="article-list-divider">-</span>
              <span class="article-list-minutes">
                
                
                  1 minute read
                
              </span>
              <span class="article-list-divider">-</span>
              <div class="article-list-tags">
                
              </div>
            </div>
          </header>

          <div class="article-content">
            <p>In previous studies we have demonstrated that the γ-aminobutryic acid-A (GABA-A) receptor antagonist oroxylin A has an awakening effect and it also represses ADHD-like behaviors (hyperactivity, impulsivity and inattention) in the spontaneously hypertensive rat (SHR) model of attention-deficit hyperactivity disorder(ADHD). We hypothesized that the effects of oroxylin A were exerted via the GABA-A receptor given the important role of the GABAergic system in ADHD. However, it is possible that aside from the GABAergic system, oroxylin A may influence other systems especially those implicated in ADHD (e.g. DAergic, etc.). To test this hypothesis, we evaluated the effects of GABA agonist, or dopamine (DA) antagonist in oroxylin A-induced alleviation of ADHD-like behaviors in SHR. SHR showed inattention and impulsivity as measured by the Y-maze and the electro-foot shock aversive water drinking tests, respectively. Oroxylin A significantly improved these behaviors, furthermore, its effect on SHR impulsivity was attenuated by haloperidol, a DA antagonist, but not by baicalein, an agonist of the GABA-A receptor. In vitro studies showed that oroxylin A inhibited DA uptake similar to methylphenidate, a dopamine transporter blocker, but did not influence norepinephrine uptake unlike atomoxetine, a selective NE reuptake inhibitor. Collectively, the present findings suggest that oroxylin A improves ADHD-like behaviors in SHR via enhancement of DA neurotransmission and not modulation of GABA pathway as previously reported. Importantly, the present study indicates the potential therapeutic value of oroxylin A in the treatment of ADHD.</p>

<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Oroxylin+A+improves+attention+deficit+hyperactivity+disorder-like+behaviors+in+the+spontaneously+hypertensive+rat+and+inhibits+reuptake+of+dopamine+in+vitro.">Read More</a></p>

          </div>

          <div class="article-share">
            
            
            <a href="https://twitter.com/home?status=Oroxylin+A+improves%C2%A0attention%C2%A0deficit%C2%A0hyperactivity%C2%A0disorder-like+behaviors+in+the+spon... - /posts/oroxylin-a-improves-attention" title="Share on Twitter" rel="noreferrer noopener" target="_blank">
              <svg viewBox="0 0 512 512"><path d="M492 109.5c-17.4 7.7-36 12.9-55.6 15.3 20-12 35.4-31 42.6-53.6 -18.7 11.1-39.4 19.2-61.5 23.5C399.8 75.8 374.6 64 346.8 64c-53.5 0-96.8 43.4-96.8 96.9 0 7.6 0.8 15 2.5 22.1 -80.5-4-151.9-42.6-199.6-101.3 -8.3 14.3-13.1 31-13.1 48.7 0 33.6 17.2 63.3 43.2 80.7C67 210.7 52 206.3 39 199c0 0.4 0 0.8 0 1.2 0 47 33.4 86.1 77.7 95 -8.1 2.2-16.7 3.4-25.5 3.4 -6.2 0-12.3-0.6-18.2-1.8 12.3 38.5 48.1 66.5 90.5 67.3 -33.1 26-74.9 41.5-120.3 41.5 -7.8 0-15.5-0.5-23.1-1.4C62.8 432 113.7 448 168.3 448 346.6 448 444 300.3 444 172.2c0-4.2-0.1-8.4-0.3-12.5C462.6 146 479 129 492 109.5z"/></svg>
            </a>
            <a href="https://www.facebook.com/sharer/sharer.php?u=/posts/oroxylin-a-improves-attention" title="Share on Facebook" rel="noreferrer noopener" target="_blank">
              <svg viewBox="0 0 512 512"><path d="M288 192v-38.1c0-17.2 3.8-25.9 30.5-25.9H352V64h-55.9c-68.5 0-91.1 31.4-91.1 85.3V192h-45v64h45v192h83V256h56.4l7.6-64H288z"/></svg>
            </a>
            <a href="https://plus.google.com/share?url=/posts/oroxylin-a-improves-attention" title="Share on Google+" rel="noreferrer noopener" target="_blank">
              <svg viewBox="0 0 128 128"><path d="M40.7 55.9v16.1c0 0 15.6 0 22 0C59.2 82.5 53.8 88.2 40.7 88.2c-13.3 0-23.7-10.8-23.7-24.2s10.4-24.2 23.7-24.2c7.1 0 11.6 2.5 15.8 5.9 3.3-3.3 3.1-3.8 11.6-11.9 -7.2-6.6-16.8-10.6-27.4-10.6C18.2 23.3 0 41.5 0 64c0 22.5 18.2 40.7 40.7 40.7 33.6 0 41.8-29.3 39-48.8H40.7zM113.9 56.7V42.6h-10.1v14.1H89.4v10.1h14.5v14.5h10.1V66.8H128V56.7H113.9z"/></svg>
            </a>
          </div>

          
        </article>
        <footer class="footer ">
  <p>
    Trineurotec.
  </p>
</footer>

      </div>
    </div>
  </main>
  

<script src="/assets/vendor.js"></script>






<script src="/assets/application.js"></script>


</body>
</html>
